Shay Shemesh
Fortuna: 33 M $ al 30/06/2026
Fortuna: 33 M $ al 30/06/2026
Shay Shemesh is the founder of Nuvectis Pharma, Inc., founded in 2020, holding the title of EVP, Chief Development & Operations Officer.
Former jobs include Head-Clinical Operations at Keryx Biopharmaceuticals, Inc. and Senior VP-Clinical & Regulatory Affairs at Stemline Therapeutics, Inc. from 2015 to 2020.
Education includes undergraduate and graduate degrees from Bar-Ilan University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NUVECTIS PHARMA, INC. 6,76 % | 13/04/2026 | 1.793.068 ( 6,76 % ) | 33 M $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| NUVECTIS PHARMA, INC. | Fundador | 27/07/2020 |
| Empresas | Cargo | Fin |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/01/2020 |
| KERYX BIOPHARMACEUTICALS | Director Técnico/Científico/I+D | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on therapies for patients with renal disease | Health Technology |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel oncology therapeutics | Health Technology |
Bar-Ilan University
Bar-Ilan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops medicines for treatment of cancer | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.